EuroIntervention:6个月支架晚期管腔丧失方面,Agent不劣于SeQuent Please-AGENT ISR试验

2020-11-13 MedSci原创 MedSci原创

冠状动脉支架内再狭窄的治疗具有挑战性。使用药物涂层球囊(DCB)是一种很有前途的技术,可以在不增加另一个金属层的情况下治疗支架内再狭窄。AGENT ISR随机试验旨在评估以前治疗过的病变的ISR患者的

冠状动脉支架内再狭窄的治疗具有挑战性。使用药物涂层球囊(DCB)是一种很有前途的技术,可以在不增加另一个金属层的情况下治疗支架内再狭窄。AGENT ISR随机试验旨在评估以前治疗过的病变的ISR患者的血管造影和临床结果,这些患者接受新涂层配方的DCB(Agent)或标准DCB(SeQuent Please)治疗,结果已在线发表于EuroIntervention
AGENT ISR是一项多中心、随机、开放标签、非劣效性研究,比较了Agent和SeQuent Please DCB。研究在欧洲的11个站点,纳入125名之前治疗过的病变长度<28 mm的支架内再狭窄患者(平均年龄约68岁,18%女性),随机分配到Agent(n=65)或SeQuent Please(n=60)。
 
结果,Agent组的主要终点--6个月支架内晚期管腔损失(0.397±0.43 mm[n=51])不劣于SeQuent Please组(0.393±0. 536 mm[n=49])(95% CI[-0.189,0.196];pnon-inferiority=0.046)。一年后,Agent和SeQuent Please患者的死亡率分别为3.1%和1.7%(p>0.99),靶病变血管重建7.7% vs 10.0%(p=0.89),支架血栓形成0% vs 3.3%(p=0.44)。两组生活质量改善情况相似。
 
综上所述,在这两个DCB的头对头比较中,在6个月内支架晚期管腔丧失方面,Agent不劣于SeQuent Please
 
原始出处:
 
Christian W Hamm, Oliver Dörr, et al., A multicentre, randomised controlled clinical study of drug-coated balloons for the treatment of coronary in-stent restenosis. EuroIntervention. 2020 Jul 17;16(4):e328-e334. doi: 10.4244/EIJ-D-19-00051.
 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1779524, encodeId=25ac1e7952479, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sun Jun 27 10:53:38 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899355, encodeId=0ca589935575, content=好东西 一定要支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/30ec60ff95c144f29d7e88e61ba9db7e/95058e87d066417181daf17bcdf446dc.jpg, createdBy=b0102305891, createdName=ms5989603601386402, createdTime=Sun Nov 15 19:30:02 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899029, encodeId=076d89902991, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ff5076455, createdName=145a3bc1m14暂无昵称, createdTime=Fri Nov 13 23:43:50 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898910, encodeId=1e2e89891022, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Fri Nov 13 11:15:27 CST 2020, time=2020-11-13, status=1, ipAttribution=)]
    2021-06-27 grace5700
  2. [GetPortalCommentsPageByObjectIdResponse(id=1779524, encodeId=25ac1e7952479, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sun Jun 27 10:53:38 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899355, encodeId=0ca589935575, content=好东西 一定要支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/30ec60ff95c144f29d7e88e61ba9db7e/95058e87d066417181daf17bcdf446dc.jpg, createdBy=b0102305891, createdName=ms5989603601386402, createdTime=Sun Nov 15 19:30:02 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899029, encodeId=076d89902991, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ff5076455, createdName=145a3bc1m14暂无昵称, createdTime=Fri Nov 13 23:43:50 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898910, encodeId=1e2e89891022, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Fri Nov 13 11:15:27 CST 2020, time=2020-11-13, status=1, ipAttribution=)]
    2020-11-15 ms5989603601386402

    好东西 一定要支持

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1779524, encodeId=25ac1e7952479, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sun Jun 27 10:53:38 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899355, encodeId=0ca589935575, content=好东西 一定要支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/30ec60ff95c144f29d7e88e61ba9db7e/95058e87d066417181daf17bcdf446dc.jpg, createdBy=b0102305891, createdName=ms5989603601386402, createdTime=Sun Nov 15 19:30:02 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899029, encodeId=076d89902991, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ff5076455, createdName=145a3bc1m14暂无昵称, createdTime=Fri Nov 13 23:43:50 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898910, encodeId=1e2e89891022, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Fri Nov 13 11:15:27 CST 2020, time=2020-11-13, status=1, ipAttribution=)]
    2020-11-13 145a3bc1m14暂无昵称

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1779524, encodeId=25ac1e7952479, content=<a href='/topic/show?id=481a2094a9' target=_blank style='color:#2F92EE;'>#Agent#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2094, encryptionId=481a2094a9, topicName=Agent)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Sun Jun 27 10:53:38 CST 2021, time=2021-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899355, encodeId=0ca589935575, content=好东西 一定要支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201030/30ec60ff95c144f29d7e88e61ba9db7e/95058e87d066417181daf17bcdf446dc.jpg, createdBy=b0102305891, createdName=ms5989603601386402, createdTime=Sun Nov 15 19:30:02 CST 2020, time=2020-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899029, encodeId=076d89902991, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65ff5076455, createdName=145a3bc1m14暂无昵称, createdTime=Fri Nov 13 23:43:50 CST 2020, time=2020-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=898910, encodeId=1e2e89891022, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220109/a91135a444374d4f8e4806c5f642b48d/00bdaaa0fa3a4c3f88477c67e48d15d1.jpg, createdBy=b0b45296453, createdName=ms20000019, createdTime=Fri Nov 13 11:15:27 CST 2020, time=2020-11-13, status=1, ipAttribution=)]
    2020-11-13 ms20000019

    学习了

    0